Breast cancer

CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.


Educational Objective: Gain insight into the use and selection of systemic therapies for patients with HR+ HER2- advanced breast cancer.
Specialty: Medical oncology, Clinical oncology, (Obstetrics & Gynaecology)
Target Audience: CME (basic, intermediate); Residents (senior)
Latest update: September 2023

Hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer is the most common subset of breast cancers. In the metastatic setting, novel therapies have expanded and shifted the treatment landscape.

Regulatory approval status of endocrine and targeted therapies for HR+ HER2- advanced or metastatic breast cancer (status 23 August 2023)